FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Cited by (1,032)

Items 101–200 of 1,032

1. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
   Edward P. Balaban, Pamela B. Mangu, Alok A. Khorana, Manish A. Shah, Somnath Mukherjee, Christopher H. Crane, Milind M. Javle, Jennifer Rachel Eads, Peter J. Allen, Andrew H. Ko et al. · 2016 · Journal of Clinical Oncology
2. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
   Gary Middleton, Paul Silcocks, Trevor F. Cox, Juan W. Valle, Jonathan Wadsley, DAVID J. PROPPER, Fareeda Y. Coxon, Paul J. Ross, Srinivasan Madhusudan, Tom W. Roques et al. · 2014 · The Lancet Oncology
3. Neoadjuvant therapy for pancreatic cancer
   Springfeld, Christoph, Ferrone, Cristina R., Katz, Matthew H. G., Philip, Philip A., Hong, Theodore S., Hackert, Thilo, Büchler, Markus W., Neoptolemos, John · 2023 · Nature Reviews Clinical Oncology
4. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer
   Kemp, Samantha B., Cheng, Noah, Markosyan, Nune, Sor, Rina, Kim, Il-Kyu, Hallin, Jill, Shoush, Jason, Quinones, Liz, Brown, Natalie V., Bassett, Jared B. et al. · 2023 · Cancer Discovery
5. The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives
   Wang, Shun, Zheng, Yan, Yang, Feng, Zhu, Le, Zhu, Xiao-Qiang, Wang, Zhe-Fang, Wu, Xiao-Lin, Zhou, Cheng-Hui, Yan, Jia-Yan, Hu, Bei-Yuan et al. · 2021 · Signal Transduction and Targeted Therapy
6. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
   Jeffrey R. Infante, Bradley G. Somer, Joon Oh Park, Chung‐Pin Li, Max Ernst Scheulen, Saifuddin M. Kasubhai, Do‐Youn Oh, Yuan Liu, Suman Redhu, Klaudia M. Steplewski et al. · 2014 · European Journal of Cancer
7. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer
   O’Kane, Grainne M., Grünwald, Barbara T., Jang, Gun-Ho, Masoomian, Mehdi, Picardo, Sarah, Grant, Robert C., Denroche, Robert E., Zhang, Amy, Wang, Yifan, Miller, Jessica K. et al. · 2020 · Clinical Cancer Research
8. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
   Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi, Richard Jackson, Christopher Michael Halloran, Charlotte Louise Rawcliffe, Rajaram Sripadam, Somnath Mukherjee, Zahir F. Soonawalla, Jonathan Wadsley et al. · 2022 · The Lancet. Gastroenterology & hepatology
9. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers
   Singhi, Aatur D., George, Ben, Greenbowe, Joel R., Chung, Jon, Suh, James, Maitra, Anirban, Klempner, Samuel J., Hendifar, Andrew, Milind, Javle M., Golan, Talia et al. · 2019 · Gastroenterology
10. Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
    Albrecht Neeße, Christian Alexander Bauer, Daniel Öhlund, Matthias Lauth, Malte Buchholz, Patrick Michl, David A. Tuveson, Thomas Mathias Gress · 2018 · Gut
11. Cell death in pancreatic cancer: from pathogenesis to therapy
    Xin Chen, Herbert J. Zeh, Rui Kang, Guido Kroemer, Daolin Tang · 2021 · Nature Reviews Gastroenterology & Hepatology
12. The role of photodynamic therapy in overcoming cancer drug resistance
    Bryan Q. Spring, Imran Rizvi, Nan Xu, Tayyaba G. Hasan · 2015 · Photochemical & Photobiological Sciences
13. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313
    Ramanathan, Ramesh K., McDonough, Shannon L., Philip, Philip A., Hingorani, Sunil R., Lacy, Jill, Kortmansky, Jeremy S., Thumar, Jaykumar, Chiorean, E. Gabriela, Shields, Anthony F., Behl, Deepti et al. · 2019 · Journal of Clinical Oncology
14. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
    Golan, Talia, Khvalevsky, Elina Zorde, Hubert, Ayala, Gabai, Rachel Malka, Hen, Naama, Segal, Amiel, Domb, Abraham, Harari, Gil, David, Eliel Ben, Raskin, Stephen et al. · 2015 · Oncotarget
15. Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
    William Greenhalf, Paula Ghaneh, John P. Neoptolemos, Daniel H. Palmer, Trevor F. Cox, Richard F. Lamb, Elizabeth Garner, Fiona Campbell, John Robert Mackey, Eithne Costello et al. · 2013 · JNCI Journal of the National Cancer Institute
16. Pancreatic cancer: why is it so hard to treat?
    Paul E. Oberstein, Kenneth P. Olive · 2013 · Therapeutic Advances in Gastroenterology
17. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer
    Sunil R. Hingorani, William Proctor Harris, Joseph Thaddeus Beck, Boris A. Berdov, Stephanie Ann Wagner, Eduard M. Pshevlotsky, Sergei Tjulandin, Oleg A. Gladkov, Randall F. Holcombe, Ronald Lee Korn et al. · 2016 · Clinical Cancer Research
18. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
    Davendra P. S. Sohal, Pamela B. Mangu, Alok A. Khorana, Manish A. Shah, Philip A. Philip, Eileen Mary O'Reilly, Hope Elizabeth Uronis, Ramesh K. Ramanathan, Christopher H. Crane, Anitra Engebretson et al. · 2016 · Journal of Clinical Oncology
19. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
    Megan M. Kaneda, Paola Cappello, Abraham V. Nguyen, Natacha Ralainirina, Chanae R. Hardamon, Philippe Foubert, Michael C. Schmid, Ping Sun, Evangeline Sari. Mose, Michael Bouvet et al. · 2016 · Cancer Discovery
20. Multivariate Modulation of the Zr MOF UiO‐66 for Defect‐Controlled Combination Anticancer Drug Delivery
    Isabel Abánades Lázaro, Connor J. R. Wells, Ross Stewart Forgan · 2020 · Angewandte Chemie International Edition
21. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX
    Theodoros P. Michelakos, Ilaria Pergolini, Carlos F. Fernandez-del Castillo, Kim C. Honselmann, Lei Cai, Vikram Deshpande, Jennifer Yon-Li Wo, David P. Ryan, Jill N. Allen, Lawrence Scott Blaszkowsky et al. · 2017 · Annals of Surgery
22. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer
    Paolo P. Provenzano, Sunil R. Hingorani · 2013 · British Journal of Cancer
23. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial
    Jessemae L. Welsh, Brett Alan Wagner, Thomas J. van ‘t Erve, Pamela S Zehr, Daniel Berg, Thorvardur Ragnar Halfdanarson, Nelson S. Yee, Kellie L. Bodeker, Juan Du, L. Jackson Roberts et al. · 2013 · Cancer Chemotherapy and Pharmacology
24. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
    Davendra P. S. Sohal, Mai Chi Duong, Syed Ameen Ahmad, Namita Sharma Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam, James Lloyd Wade, Elena Gabriela Chiorean, Katherine Adams Guthrie, Andrew M. Lowy et al. · 2021 · JAMA Oncology
25. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
    Jonathan G. Pol, Erika Vacchelli, Fernando Aranda, Francesca Castoldi, Alexander M.M. Eggermont, Isabelle Cremer, Catherine Sautès‐Fridman, Jitka Palich Fucikova, Jérôme Galon, Radek Špíšek et al. · 2015 · OncoImmunology
26. Microbiota in pancreatic health and disease: the next frontier in microbiome research
    Ryan Michael Thomas, Christian Jobin · 2019 · Nature Reviews Gastroenterology & Hepatology
27. Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
    Edward Jae-Hoon Kim, Vaibhav Sahai, Ethan V. Abel, Kent A. Griffith, Joel K. Greenson, Naoko Takebe, Gazala Naaz Khan, John Blau, Ronald A. Craig, Ulysses J. Balis et al. · 2014 · Clinical Cancer Research
28. Pancreatic Adenocarcinoma, Version 2.2012
    Margaret A. Tempero, J. Pablo Arnoletti, Stephen W. Behrman, Edgar Ben‐Josef, Al B. Benson, Ephraim S. Casper, Steven J. Cohen, Brian G. Czito, Joshua D.I. Ellenhorn, William G. Hawkins et al. · 2012 · Journal of the National Comprehensive Cancer Network
29. Recent progress in non-native nucleic acid modifications
    Luke K. McKenzie, Roberto El-Khoury, James D. Thorpe, Masad José Damha, Marcel Hollenstein · 2021 · Chemical Society Reviews
30. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial
    Aparna R. Parikh, Annamária Szabolcs, Jill N. Allen, Jeffrey William Clark, Jennifer Yon-Li Wo, Michael J. Raabe, Hannah L. Thel, David Hoyos, Arnav Mehta, Sanya Arshad et al. · 2021 · Nature Cancer
31. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
    Quisette P. Janssen, Stefan Buettner, Mustafa Suker, Berend R. Beumer, Pietro Addeo, Philippe Bachellier, Nathan Bahary, Tanios Bekaii‐Saab, Maria Antonietta Bali, Marc G. Besselink et al. · 2019 · JNCI Journal of the National Cancer Institute
32. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
    Thomas Benjamin Karasic, Mark H. O’Hara, Arturo Loaiza‐Bonilla, Kim A. Reiss, Ursina R. Teitelbaum, Erkut Hasan Borazanci, Ana De Jesus‐Acosta, Colleen Redlinger, Jessica A. Burrell, Daniel A. Laheru et al. · 2019 · JAMA Oncology
33. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
    Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Oettle, Helmut, Kozloff, Mark, Cleverly, Ann et al. · 2018 · British Journal of Cancer
34. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
    Marianne Sinn, Marcus Bahra, Torsten Liersch, Klaus Gellert, Helmut Messmann, Wolf O. Bechstein, Dirk Waldschmidt, Lutz Jacobasch, Martin Wilhelm, Bettina Rau et al. · 2017 · Journal of Clinical Oncology
35. Extended pancreatectomy in pancreatic ductal adenocarcinoma: Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS)
    Werner Hartwig, Charles M. Vollmer, Abe L. Fingerhut, Charles J. Yeo, John P. Neoptolemos, Mustapha Adham, Åke Andrén‐Sandberg, Horacio J. Asbun, Claudio Bassi, Max Bockhorn et al. · 2014 · Surgery
36. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
    Sharlene Gill, Yoo‐Joung Ko, C. Cripps, Annie Beaudoin, Sukhbinder Dhesy‐Thind, Muhammad Zulfiqar, Pawel Zalewski, Thuan Do, Pablo Cano, Wendy Yin Han Lam et al. · 2016 · Journal of Clinical Oncology
37. Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment
    Kim-Fuchs, Corina, Le, Caroline P., Pimentel, Matthew A., Shackleford, David, Ferrari, Davide, Angst, Eliane, Hollande, Frédéric, Sloan, Erica K. · 2014 · Brain, Behavior, and Immunity
38. Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity
    Wallace, Bret D., Roberts, Adam B., Pollet, Rebecca M., Ingle, James D., Biernat, Kristen A., Pellock, Samuel J., Venkatesh, Madhu Kumar, Guthrie, Leah, O’Neal, Sara K., Robinson, Sara J. et al. · 2015 · Chemistry & Biology
39. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
    Ashton Anthony Connor, Robert Edward Denroche, Gun Ho Jang, Lee E. Timms, Sangeetha N. Kalimuthu, Iris Selander, Treasa A. McPherson, Gavin W. Wilson, Michelle Chan‐Seng‐Yue, Ivan Borozan et al. · 2016 · JAMA Oncology
40. Current status and progress of pancreatic cancer in China
    Quanjun Lin · 2015 · World Journal of Gastroenterology
41. Chemotherapy for pancreatic cancer
    Christoph Springfeld, Dirk Jäger, Markus Wolfgang Büchler, Oliver Strobel, Thilo Hackert, Daniel H. Palmer, John P. Neoptolemos · 2019 · La Presse Médicale
42. FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
    Jason Edward Faris, Lawrence Scott Blaszkowsky, Shaunagh McDermott, Alexander R. Guimarães, Jackie D. Szymonifka, Mai Anh Huynh, Cristina Rosa Ferrone, Jennifer Ann Wargo, Jill N. Allen, Lauren Elizabeth Dias et al. · 2013 · The Oncologist
43. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
    Freed-Pastor, William A., Lambert, Laurens J., Ely, Zackery A., Pattada, Nimisha B., Bhutkar, Arjun, Eng, George, Mercer, Kim L., Garcia, Ana P., Lin, Lin, Rideout, William M. et al. · 2021 · Cancer Cell
44. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
    Daniel Pietrasz, Nicolas Pécuchet, Fanny Garlan, Audrey Didelot, Olivier Dubreuil, Solène Doat, Françoise Imbert‐Bismut, Mehdi Karoui, Jean‐Christophe Vaillant, Valérie Taly et al. · 2016 · Clinical Cancer Research
45. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship
    Maximilian Weniger, Kim C. Honselmann, Andrew Scott Liss · 2018 · Cancers
46. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer
    Shinya Okumura, Toshimi Kaido, Yuhei Hamaguchi, Yasuhiro Fujimoto, Toshihiko Masui, Masaki Mizumoto, Ahmed Hammad, Akira Mori, Kyoichi Takaori, Shinji Üemoto · 2015 · Surgery
47. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
    Uwe Pelzer, Bernhard Opitz, Gerd Deutschinoff, Martina Beate Stauch, P Reitzig, Sabine Hahnfeld, Lothar Müller, Martina Grunewald, Jens Stieler, Marianne Sinn et al. · 2015 · Journal of Clinical Oncology
48. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
    Paola Martinelli, Enrique Carrillo de Santa Pau, Trevor F. Cox, Bruno Sáinz, Nelson Dusetti, William Greenhalf, Lorenzo Rinaldi, Eithne Costello, Paula Ghaneh, Núria Malats et al. · 2016 · Gut
49. Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer
    Khine Nyein Myint, Riya Biswas, Yan Li, Nancy N. Jong, Stephen M. F. Jamieson, Johnson Liu, Catherine HyeWon Han, Christopher John Squire, Fabrice Mérien, Jun Lu et al. · 2019 · Scientific Reports
50. Trial watch
    Erika Vacchelli, Laura Senovilla, Alexander M.M. Eggermont, Wolf H. Fridman, Jérôme Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2013 · OncoImmunology
51. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer
    Xiangsheng Liu, Allen Situ, Yanan Kang, Katie Rose Villabroza, Yu‐Pei Liao, Chong Hyun Chang, Timothy R. Donahue, André E. Nel, Huan Meng · 2016 · ACS Nano
52. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial
    Michele Reni, Gianpaolo Balzano, Silvia Matilde Zanon, Alessandro Zerbi, Lorenza Rimassa, Renato Castoldi, Domenico Pinelli, Stefania Mosconi, Claudio Doglioni, Marta Chiaravalli et al. · 2018 · The Lancet. Gastroenterology & hepatology
53. Metallodrugs in cancer nanomedicine
    Peña, Quim, Wang, Alec, Zaremba, Orysia, Shi, Yang, Scheeren, Hans W., Metselaar, Josbert M., Kiessling, Fabian, Pallares, Roger M., Wuttke, Stefan, Lammers, Twan · 2022 · Chemical Society Reviews
54. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
    Leila Khoja, Alison Catherine Backen, Robert A. Szczepaniak Sloane, Lia P. Menasce, W. David J. Ryder, Matthew Krebs, R Board, Glen Clack, Andrew M. Hughes, Fiona Helen Blackhall et al. · 2011 · British Journal of Cancer
55. DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma
    Geng Zhang, Aaron J. Schetter, Peijun He, Naotake Funamizu, Jochen Gaedcke, Β. Michael Ghadimi, Thomas Ried, Raffit Hassan, Harris G. Yfantis, Dong Ho Lee et al. · 2012 · PLoS ONE
56. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
    Daniel R. Principe, Patrick W. Underwood, Murray Korc, Jose Gilberto Trevino, Hidayatullah G. Munshi, Ajay Rana · 2021 · Frontiers in Oncology
57. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
    Philip A. Philip, Jill Lacy, Fabienne Portales, Alberto F. Sobrero, Roberto Pazo-Cid, José Luis Manzano Mozo, Edward Jae-Hoon Kim, Scot D. Dowden, Ahmed Zakari, Christophe Borg et al. · 2020 · The Lancet. Gastroenterology & hepatology
58. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
    Vivek Subbiah, Philippe Alexandre Cassier, Salvatore Siena, Elena Garralda, Luis G Paz-Ares, Pilar Garrido, Ernest Nadal, Jacqueline Vuky, Gilberto L Lopes Junior, Gregory Peter Kalemkerian et al. · 2022 · Nature Medicine
59. Drug resistance in pancreatic cancer: Impact of altered energy metabolism
    Cristoforo Grasso, Gerrit Jansen, Elisa Giovannetti · 2017 · Critical Reviews in Oncology/Hematology
60. Adaptive trial designs: a review of barriers and opportunities
    Kairalla, John A, Coffey, Christopher S, Thomann, Mitchell A, Muller, Keith E · 2012 · Trials
61. Screening for Pancreatic Cancer: Why, How, and Who?
    Poruk, Katherine E., Firpo, Matthew A., Adler, Douglas G., Mulvihill, Sean J. · 2013 · Annals of Surgery
62. Translational advances in pancreatic ductal adenocarcinoma therapy
    Abdel Nasser Hosein, Stephanie K. Dougan, Andrew J. Aguirre, Anirban Maitra · 2022 · Nature Cancer
63. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma
    Timothy Chao, Emma Elizabeth Furth, Robert H. Vonderheide · 2016 · Cancer Immunology Research
64. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
    Albrecht Neeße, Kristopher K. Frese, Tashinga E. Bapiro, Tomoaki Nakagawa, Mark D. Sternlicht, Todd W. Seeley, Christian P. Pilarsky, Duncan Ian Jodrell, Suzanne M. Spong, David A. Tuveson · 2013 · Proceedings of the National Academy of Sciences
65. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
    Pishvaian, Michael J., Bender, Robert J., Halverson, David, Rahib, Lola, Hendifar, Andrew E., Mikhail, Sameh, Chung, Vincent, Picozzi, Vincent J., Sohal, Davendra, Blais, Edik M. et al. · 2018 · Clinical Cancer Research
66. Overall survival results from the POLO trial: A Phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer
    Kindler, Hedy L., Hammel, Pascal, Reni, Michele, Van Cutsem, Eric, Macarulla, Teresa, Hall, Michael J., Park, Joon Oh, Hochhauser, Daniel, Arnold, Dirk, Oh, Do-Youn et al. · 2022 · Journal of Clinical Oncology
67. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
    Knut Jørgen Labori, Svein Olav Bratlie, Bodil Andersson, Jon‐Helge Angelsen, Christina Biörserud, Bergþór Björnsson, Erling Audun Bringeland, Nils Elander, Herish Garresori, Jon Erik Grønbech et al. · 2024 · The Lancet. Gastroenterology & hepatology
68. Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
    Marlo A. Blazer, Christina Sing-Ying Wu, Richard M. Goldberg, Gary S. Phillips, Carl Richard Schmidt, Peter Muscarella, Evan John Wuthrick, Terrence M. Williams, Joshua Reardon, Edwin Christopher Ellison et al. · 2014 · Annals of Surgical Oncology
69. The Immune Microenvironment in Pancreatic Cancer
    Magdalena Huber, Corinna U. Brehm, Thomas Mathias Gress, Malte Buchholz, Bilal Alashkar Alhamwe, Elke Pogge von Strandmann, Emily P. Slater, Jörg Walter Bartsch, Christian Alexander Bauer, Matthias Lauth · 2020 · International Journal of Molecular Sciences
70. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma
    Giovanni Francesco Castino, Nina Cortese, Giovanni Luigi Capretti, Simone Serio, Giuseppe Di Caro, Rossana Mineri, Elena Illica Magrini, Fabio Grizzi, Paola Cappello, Francesco Novelli et al. · 2015 · OncoImmunology
71. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
    Eric Scott Christenson, Elizabeth M. Jaffee, Nilofer Saba Azad · 2020 · The Lancet Oncology
72. Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
    Lucy Ireland, Almudena Santos, Muhammad S. Ahmed, Carolyn Rainer, Sebastian Rune Nielsen, Valeria Quaranta, Ulrike Weyer-Czernilofsky, Dannielle D. Engle, Pedro Antonio Pérez-Mancera, Sarah E. Coupland et al. · 2016 · Cancer Research
73. Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
    Raphaël Maréchal, Jean‐Baptiste Bachet, John Robert Mackey, Cécile Dalban, Pieter Demetter, Kathryn Graham, Anne Couvelard, Magali Svrcek, Armelle Bardier–Dupas, Pascal R. Hammel et al. · 2012 · Gastroenterology
74. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma
    Eric A. Mellon, Sarah E. Hoffe, Gregory M. Springett, Jessica M. Frakes, Tobin Joel Crill Strom, Pamela Joy Hodul, Mokenge Peter Malafa, Michael David Chuong, Ravi Shridhar · 2015 · Acta Oncologica
75. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
    Christoph Heining, Peter Horak, Sebastian Uhrig, Paula Codó, Barbara Klink, Barbara Hutter, Martina Fröhlich, David Bonekamp, Daniela Richter, Katja Steiger et al. · 2018 · Cancer Discovery
76. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
    Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye H. Simpson, Scott Mead, Marc D. Jones, Jaswinder Singh Samra, Anthony James Gill et al. · 2015 · Clinical Cancer Research
77. Surgical Outcome Results From SWOG S1505
    Syed Arif Ahmad, Mai Chi Duong, Davendra P. S. Sohal, Namita Sharma Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam, James Lloyd Wade, Elena Gabriela Chiorean, Katherine Adams Guthrie, Andrew M. Lowy et al. · 2020 · Annals of Surgery
78. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
    Wungki Park, Jiapeng Chen, Joanne F. Chou, Anna M. Varghese, Kenneth H. Yu, Winston Wong, Marinela Capanu, Vinod P. Balachandran, Caitlin A. McIntyre, Imane El Dika et al. · 2020 · Clinical Cancer Research
79. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer
    Naim U. Rashid, Xianlu L. Peng, Chong Jin, Richard A. Moffitt, Keith E. Volmar, Brian A. Belt, Roheena Z. Panni, Timothy M. Nywening, Silvia G. Herrera, Kristin J. Moore et al. · 2019 · Clinical Cancer Research
80. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
    Pavan P. Adiseshaiah, Rachael M. Crist, Sara S. Hook, Scott E. McNeil · 2016 · Nature Reviews Clinical Oncology
81. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
    David Balli, Andrew J. Rech, Ben Z. Stanger, Robert H. Vonderheide · 2016 · Clinical Cancer Research
82. Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma
    Boone, Brian A., Bahary, Nathan, Zureikat, Amer H, Moser, A. James, Normolle, Daniel P, Wu, Wen-Chi, Singhi, Aatur D., Bao, Phillip, Bartlett, David L, Liotta, Lance A et al. · 2015 · Annals of Surgical Oncology
83. The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
    Peter J. Kahrilas, Guy E. Boeckxstaens · 2013 · Gastroenterology
84. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
    Angela Tatiana Alistar, Bonny B. Morris, Rodwige Desnoyer, Heidi D. Klepin, Keyanoosh Hosseinzadeh, Clancy J. Clark, Amy Cameron, John R. Leyendecker, Ralph D'Agostino, Ümit Topaloĝlu et al. · 2017 · The Lancet Oncology
85. The Role of Mitochondria in Inflammation: From Cancer to Neurodegenerative Disorders
    Sonia Missiroli, Ilaria Genovese, Mariasole Perrone, Bianca Vezzani, Veronica Angela Maria Vitto, Carlotta Giorgi · 2020 · Journal of Clinical Medicine
86. Co-delivery of drugs and plasmid DNA for cancer therapy
    Pei Y. Teo, Wei Cheng, James L. Hedrick, Yi Yan Yang · 2015 · Advanced Drug Delivery Reviews
87. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
    Peter J. Hosein, Jessica MacIntyre, Carolina Kawamura, Jennifer Cudris Maldonado, Vinicius Ernani, Arturo Loaiza‐Bonilla, Govindarajan Narayanan, Afonso C. Ribeiro, Lorraine Portelance, Jaime Rafael Merchan et al. · 2012 · BMC Cancer
88. Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies
    Ciara Marie Kelly, Armin Shahrokni · 2016 · Journal of Oncology
89. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
    Jordan Michael Winter, Charles J. Yeo, Jonathan Robert Brody · 2012 · Journal of Surgical Oncology
90. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
    Michele Cioffi, Sara Maria David Trabulo, Manuel M. Hidalgo, Eithne Costello, William Greenhalf, Mert Erkan, Jorg H. Kleeff, Bruno Sáinz, Christopher Heeschen · 2015 · Clinical Cancer Research
91. Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma
    Govindarajan Narayanan, Peter J. Hosein, Geetika Arora, Katuzka J. Barbery, Tatiana Froud, Alan S. Livingstone, Dido Franceschi, Caio M. Rocha Lima, Jose M. Yrizarry · 2012 · Journal of Vascular and Interventional Radiology
92. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis
    Yuki Yamaguchi, Takashi Kasukabe, Shunichi Kumakura · 2018 · International Journal of Oncology
93. Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy
    Aadra Prashant Bhatt, Samuel J. Pellock, Kristen A. Biernat, William G. Walton, Bret D. Wallace, Benjamin C. Creekmore, Marine P. M. Letertre, Jonathan Richard Swann, Ian D. Wilson, Jose Roques et al. · 2020 · Proceedings of the National Academy of Sciences
94. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial
    Udo Rudloff, Russell Charles Langan, John E. Mullinax, Joal D. Beane, Seth M. Steinberg, Tatiana H. Beresnev, Carole C. Webb, Melissa Walker, Mary Ann Toomey, David S. Schrump et al. · 2014 · Journal of Surgical Oncology
95. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery
    Willemieke S. F. J. Tummers, Jesse V. Groen, Babs G. Sibinga Mulder, Arantza Fariña Sarasqueta, J. Morreau, Hein Putter, Cornelis JH van de Velde, Alexander L. Vahrmeijer, Bert A. Bonsing, J. Sven D. Mieog et al. · 2019 · British journal of surgery
96. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer
    De‐Shen Wang, Hui Luo, Miao‐Zhen Qiu, Zhiqiang Wang, Dong-sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui‐Hua Xu · 2012 · Medical Oncology
97. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations
    Lei Huang, Lina Jansen, Yesilda Balavarca, Esther Molina‐Montes, Masoud Babaei, Lydia G. van der Geest, V.E.P.P. Lemmens, Liesbet J. Van Eycken, Harlinde De Schutter, Tom Børge Johannesen et al. · 2017 · Gut
98. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
    Tianyi Zhang, Yanxian Ren, Pengfei Yang, Jufang Wang, Heng Zhou · 2022 · Cell Death and Disease
99. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
    Lowery, Maeve A, Wong, Winston, Jordan, Emmet J, Lee, Jonathan W, Kemel, Yelena, Vijai, Joseph, Mandelker, Diana, Zehir, Ahmet, Capanu, Marinela, Salo-Mullen, Erin et al. · 2018 · JNCI: Journal of the National Cancer Institute
100. Outcomes and endpoints in trials of cancer treatment: the past, present, and future
     Michelle K. Wilson, Katherine Karakasis, Amit M. Oza · 2014 · The Lancet Oncology